What Is Veozah (Fezolinetant), and How Does the New 2026 Data Change the Hot-Flash Conversation?

"HRT is not an option for me, so what actually works for hot flashes?" That question has had very few good answers. Until recently, the only FDA-approved non-hormonal option was an antidepressant at a low dose. A new class of drugs is changing that.

Key Takeaways

• A June 2026 real-world study of 656 women found fezolinetant improved hot flashes, depression, and anxiety in as few as 4 weeks (Endocrine Society, 2026).
• Fezolinetant is the first FDA-approved non-hormonal medication specifically targeting hot flashes (FDA, 2023).
• Liver enzyme monitoring is required for the first 9 months; the drug is not appropriate for everyone.

Why Is a Non-Hormonal Hot-Flash Drug a Big Deal?

Hot flashes affect roughly 80% of women during menopause. Hormone therapy works well, but it is not suitable for women with hormone-sensitive breast cancer, those over 65, or anyone who prefers to avoid systemic hormones. For decades, clinicians had little beyond SSRIs, gabapentin, or lifestyle tweaks to offer (Parsemus Foundation, 2026).

Citation capsule: The first real-world study of fezolinetant reports that hot flashes and night sweats improved significantly from pretreatment through 12 weeks, with depression and anxiety scores improving as early as 4 weeks (Endocrine Society, 2026).

Fezolinetant changes that. It is an NK3 receptor antagonist that blocks the brain signals driving hot flashes without touching estrogen or progesterone.

What Did the 2026 Real-World Data Show?

The OPTION-VMS study, presented at ENDO 2026, included 656 women ages 40 to 75 prescribed fezolinetant or other non-hormonal therapies. In women using fezolinetant (n=201), hot flashes improved significantly at 4, 8, and 12 weeks. Depressive and anxiety symptoms also improved (Endocrine Society, 2026).

That matters because hot flashes are not just temperature events. They disrupt sleep, erode mood, and damage quality of life.

See our perimenopause sleep guide for why night sweats fragment rest, and our estrogen risk and benefit guide for the hormonal conversation.

Who Should Consider Fezolinetant?

Women who cannot or choose not to use hormone therapy are the core candidates. That includes breast cancer survivors, women over 65, and anyone with a history of blood clots or stroke who wants to avoid estrogen. Real-world data shows that about 20.5% of fezolinetant users have a breast cancer diagnosis, confirming adoption by this group (Parsemus Foundation, 2026).

[UNIQUE INSIGHT] The nuance is that fezolinetant does not protect bone, heart, or brain the way estrogen does. It treats vasomotor symptoms only. Women who need broader menopausal care still need a comprehensive plan, not a single pill.

What Are the Risks and Monitoring Requirements?

Fezolinetant carries a warning for elevated liver enzymes. The FDA requires blood tests before starting and during the first 9 months of therapy. Most side effects in trials were mild—headache, diarrhea, back pain, and insomnia—but liver tracking is non-negotiable (Parsemus Foundation, 2026).

Frequently Asked Questions

Is fezolinetant a hormone?

No. It is a neurokinin receptor antagonist that acts in the brain's thermoregulatory center without altering circulating estrogen or progesterone (Parsemus Foundation, 2026).

Can I take fezolinetant if I had breast cancer?

Clinicians prescribe it to breast cancer survivors because it is non-hormonal, but confirm with your oncologist. A 2026 review called for longer-term safety data in this group (Parsemus Foundation, 2026).

How fast does it work?

Improvements in hot flash frequency can appear by 4 weeks (Endocrine Society, 2026).

Will insurance cover Veozah?

Many plans cover it for menopausal vasomotor symptoms, but prior authorization and out-of-pocket costs vary. Discount programs exist for uninsured patients.

Does elinzanetant offer something different?

Yes. Elinzanetant (Lynkuet) is a dual NK1/NK3 antagonist that also improves sleep quality. It is emerging as another non-hormonal option with a slightly different side-effect profile (Parsemus Foundation, 2026).

Conclusion

Fezolinetant does not replace hormone therapy for women who want broader menopausal protection, but it fills a genuine gap for women who need vasomotor relief without estrogen. For the broader hormonal picture, see our estrogen risk and benefit guide and perimenopause sleep guide.

Cluster: This article belongs to our women's health and longevity cluster. For the broad overview, see our women's longevity hub. For related topics, explore estrogen risk and benefit, perimenopause sleep, and menopausal weight gain.